AI Insight
The LITESPARK-011 phase 3 trial compared belzutifan plus lenvatinib against cabozantinib in patients with advanced clear-cell renal cell carcinoma who had disease progression after prior anti-PD-1 or anti-PD-L1 therapy. While overall survival did not differ significantly between treatment groups, the belzutifan-lenvatinib combination demonstrated efficacy and a safety profile consistent with the individual drugs. The results suggest belzutifan-lenvatinib may represent a new standard of care option for this patient population.
Why it matters
This trial establishes an alternative treatment option for patients with advanced renal cell carcinoma whose disease has progressed despite immunotherapy, addressing an important unmet clinical need. The novel drug combination expands the therapeutic arsenal available to oncologists treating this challenging patient population in the second-line setting.
Belzutifan–lenvatinib represents a novel and efficacious treatment option. Although overall survival was not significantly different between the groups, belzutifan–lenvatinib might be a new standard of care for patients with advanced clear-cell renal cell carcinoma with disease progression after previous anti-PD-1 or anti-PD-L1 therapy. The safety profile of belzutifan–lenvatinib was consistent with those of the individual drugs.